PCSK9 and familial hyperaldosteronism: In this study, we aimed (1) to examine the effect of treatment by monoclonal antibodies against PCSK9 on different aggregatory cascades using 7 platelet aggregation triggers as well as on the antiplatelet potency of three clinically used drugs in FH patients, and (2) to compare platelet responses to these triggers and antiplatelet drugs between FH patients and age-matched generally healthy controls.